- Research
In vitro development of a new personalized therapy for patients with neurofibromatosis type 2
Researchers from the Clinical Genomics group of the Germans Trias i Pujol Research Institute (IGTP) and the Genetics Service of the Germans Trias Hospital (HUGTiP) have developed a new in vitro therapy to recover part of the function encoded by the gene NF2, which, when altered, induces the development of neurofibromatosis type 2. The study has been published in the prestigious journal Molecular Therapy Nucleic Acids.
_1670407077.jpg)
